Vol. 18/No. 18

PEGPH20 (pegvorhyaluronidase alfa), a novel formulation of a naturally occuring enzyme, is being investigated as a biomarker-driven treatment for patients with advanced pancreatic cancer.

For the past 5 years, Montefiore has been a leading Pioneer Accountable Care Organization (ACO) in CMS’ ACO program, which aims to improve the quality of care for Medicare beneficiaries while identifying ways to save healthcare dollars.

Although dual HER2 blockade strategies have become an important part of the treatment paradigm for patients with HER2-positive breast cancer, the complexities of administering these therapies continue to unfold.

Recent approval of immunotherapy in the first-line setting for treatment of patients with locally advanced and metastatic non–small cell lung cancer without driver mutations represents changes in care.

The clinical oncology community, along with patients, families, pharmaceutical companies, investors, and third-party payers, eagerly awaits the plenary session presentations at the ASCO annual meetings as representing the most important and impactful of the thousands of abstracts submitted each year.

EZH2 have been frequently observed in cancer, and small molecule inhibitors have been developed against the enzymatic activity of EZH2, with evidence of clinical activity in early-phase trials.

Although there have improvements in the treatment of men with prostate cancer during the past 15 years, patients with advanced disease continue to pose a clinical challenge.